Publications
2023
Dzhangar Dzhumashev, Stenija Anton-Joseph, Victoria J Morel, Andrea Timpanaro, Gregor Bordon, Caroline Piccand, Simone Aleandri, Paola Luciani, Jochen Rössler, Michele Bernasconi
Rapid liposomal formulation for nucleolin targeting to rhabdomyosarcoma cells
Eur J Pharm Biopharm 2023 Nov 27:S0939-6411(23)00309-0. Online ahead of print
Andrea Timpanaro†, Caroline Piccand†, Dzhangar Dzhumashev, Stenija Anton‑Joseph3, Andrea Robbi, Janine Moser, Jochen Rössler and Michele Bernasconi
CD276‑CAR T cells and Dual‑CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models.
J Exp Clin Cancer Res 2023: 42:293
Timpanaro A, Piccand C, Uldry A-C, Bode PK, Dzhumashev D, Sala R, Heller M, Rössler J and Bernasconi M
Surfaceome Profiling of Cell Lines and Patient-Derived Xenografts Confirm FGFR4, NCAM1, CD276, and Highlight AGRL2, JAM3, and L1CAM as Surface Targets for Rhabdomyosarcoma.
Int J Mol Sci 2023;24:2601
2022
Dzhumashev, D.; Timpanaro, A.; Ali, S.; De Micheli, A.J.; Mamchaoui, K.; Cascone, I.; Rössler, J.; Bernasconi, M.
Quantum Dot-Based Screening Identifies F3 Peptide and Reveals Cell Surface Nucleolin as a Therapeutic Target for Rhabdomyosarcoma.
2020
Alijaj, N.; Moutel, S.; Gouveia, Z.L.; Gray, M.; Roveri, M.; Dzhumashev, D.; Weber, F.; Meier, G.; Luciani, P.; Rössler, J.K.; Schäfer, B.W.; Perez, F.; Bernasconi, M.
Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma.
Daurat, M., Nguyen, C., Dominguez Gil, S., Sol, V., Chaleix, V., Charnay, C., Raehm, L., El Cheikh, K., Morere, A., Bernasconi, M., Timpanaro, A., Garcia, M., Cunin, F., Roessler, J., Durand, J. O. & Gary-Bobo, M.
The mannose 6-phosphate receptor targeted with porphyrin-based periodic mesoporous organosilica nanoparticles for rhabdomyosarcoma theranostics.
2019
Bernasconi, M., Dzhumashev, D., Timpanaro, A. & Rössler, J.
Targeted therapies for rhabdomyosarcoma.
Selected earlier publications
Roveri, M., Pfohl, A., Jaaks, P., Alijaj, N., Leroux, J. C., Luciani, P. & Bernasconi, M.
Prolonged circulation and increased tumor accumulation of liposomal vincristine in a mouse model of rhabdomyosarcoma
Nanomedicine (Lond) 12, 1135-1151, (2017)
Roveri, M., Bernasconi, M., Leroux, J. C. & Luciani, P.
Peptides for tumor-specific drug targeting: state of the art and beyond
J Mater Chem B 5, 4348-4364, (2017)
Jaaks, P. & Bernasconi, M.
The proprotein convertase furin in tumour progression.
Int J Cancer 141, 654–663 (2017)
Jaaks, P., Meier, G., Alijaj, N., Brack, E., Bode, P., Koscielniak, E., Wachtel, M., Schafer, B. W. & Bernasconi, M.
The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells
Oncotarget 7, 76743-76755, (2016)
Jaaks, P., D'Alessandro, V., Grob, N., Buel, S., Hajdin, K., Schafer, B. W. & Bernasconi, M.
The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion
Rengaswamy, V., Zimmer, D., Suss, R. & Rossler, J.
RGD liposome-protamine-siRNA (LPR) nanoparticles targeting PAX3-FOXO1 for alveolar rhabdomyosarcoma therapy
Scherzinger-Laude, K., Schonherr, C., Lewrick, F., Suss, R., Francese, G. & Rossler, J.
Treatment of neuroblastoma and rhabdomyosarcoma using RGD-modified liposomal formulations of patupilone (EPO906).
Int J Nanomedicine 8, 2197-2211, (2013)
Rengaswamy, V., Kontny, U. & Rossler, J.
New approaches for pediatric rhabdomyosarcoma drug discovery: targeting combinatorial signaling.
Expert Opin Drug Discov 6, 1103-1125, (2011)
Hajdin, K., D'Alessandro, V., Niggli, F. K., Schafer, B. W. & Bernasconi, M.
Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.
Striepe, S., Rössler, J. & Süss, R.
Integrin- and IGF1-receptor-mediated liposomal siRNA delivery to alveolar rhabdomyosarcoma cells.
Gantert, M., Lewrick, F., Adrian, J. E., Rossler, J., Steenpass, T., Schubert, R. & Peschka-Suss, R.
Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors.
Pharm. Res. 26, 529-538, (2009)
Witt, H., Hajdin, K., Iljin, K., Greiner, O., Niggli, F. K., Schafer, B. W. & Bernasconi, M.
Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1.
Int. J. Cancer 124, 2026-2032, (2009)
Joyce, J. A., Laakkonen, P., Bernasconi, M., Bergers, G., Ruoslahti, E. & Hanahan, D.
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis.
Cancer Cell 4, 393-403, (2003)
Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H., Bredesen, D., Pasqualini, R. & Ruoslahti, E.
Targeting the prostate for destruction through a vascular address.
Proc. Natl. Acad. Sci. U. S. A. 99, 1527-1531, (2002)
Porkka, K., Laakkonen, P., Hoffman, J. A., Bernasconi, M. & Ruoslahti, E.
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo.
Proc. Natl. Acad. Sci. U. S. A. 99, 7444-7449, (2002)
Margue, C. M., Bernasconi, M., Barr, F. G. & Schafer, B. W.
Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR.
Oncogene 19, 2921-2929, (2000)
Bernasconi, M., Remppis, A., Fredericks, W. J., Rauscher, F. J., 3rd & Schafer, B. W.